Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS and AstraZeneca are expanding their collaboration to accelerate global liquid biopsy testing deployment. The partnership will extend MSK-ACCESS powered with SOPHiA DDM to 30 clinical institutions worldwide in 2025.

Key highlights:

• The liquid biopsy test detects genomic alterations from a single blood draw using advanced algorithms to analyze circulating tumor DNA
• This testing method offers advantages when traditional tissue biopsies are impractical due to cost, time, or invasiveness
• New data presented at AACR shows consistent accuracy across different laboratory settings

The expanded rollout supports AstraZeneca's real-world evidence initiatives and aims to validate decentralized liquid biopsy testing's clinical impact. The collaboration addresses a major industry challenge, as site-to-site result consistency has historically limited liquid biopsy adoption. Recent study results confirm the test maintains high analytical performance across multiple centers, matching the original standards set at Memorial Sloan Kettering Cancer Center.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before U.S. markets open. The company will host a conference call to discuss the results and business outlook at 8:00 a.m. EDT / 2:00 p.m. CET on the same day. Investors can access the live webcast through the SOPHiA GENETICS Investor Relations Website, where a replay will also be available after the event.

SOPHiA GENETICS (SOPH) and Precision for Medicine have announced a strategic partnership to enhance biomarker discovery and precision medicine services. The collaboration integrates the SOPHiA DDM™ Platform into Precision for Medicine's offerings, providing advanced AI-driven analytics for clinical trials.

The partnership will leverage AI algorithms to analyze multimodal data, including genomic, radiomic, and clinical information, enabling better patient population targeting for clinical trials. A key feature includes the integration of MSK-ACCESS® powered with SOPHiA DDM™, a liquid biopsy test supported by AstraZeneca, which will facilitate retrospective clinical trial data analysis and improve patient stratification.

The collaboration combines Precision for Medicine's wet lab services and clinical trial expertise with SOPHiA GENETICS' AI-based genomic analysis tools, creating a comprehensive solution for biopharma companies to accelerate drug development, particularly in oncology, rare diseases, and genetic disorders.

SOPHiA GENETICS (Nasdaq: SOPH) has achieved a significant milestone by analyzing over two million patient genomic profiles through its AI-powered SOPHiA DDM™ Platform. This achievement, announced at NVIDIA GTC, represents a doubling of analyzed profiles since 2022.

The platform currently serves 800 healthcare institutions across 72 countries, processing thousands of oncology and rare disease cases daily. SOPHiA DDM™'s AI capabilities are uniquely shaped by real-world data, enabling faster and more accurate treatment decisions.

Healthcare professionals worldwide have reported significant benefits from the platform:

• CHU Lyon, France reports faster and more efficient analysis of hereditary cardiac pathologies
• Karkinos Healthcare in India has expanded advanced cancer diagnostics to underserved communities
• Fondazione Policlinico Universitario Gemelli in Italy utilizes the platform for various genetic analyses
• UCSF Clinical Cancer Genomics Lab successfully identifies complex genetic rearrangements in cancer cases

SOPHiA GENETICS (SOPH) reported Q4 2024 revenue of $17.7M, up 4% YoY, and full-year 2024 revenue of $65.2M, also up 4% YoY. The company achieved record analysis volumes with 352,000 analyses in FY2024, representing 11% YoY growth.

Key operational metrics include:

• Q4 gross margin of 68.2% (reported) and 74.2% (adjusted)
• Operating loss improved by 8% to $17.4M (reported) and 23% to $10.2M (adjusted)
• Reached 472 core genomics customers, up from 450 in Q4 2023
• Signed 92 new customers in FY2024

For 2025, SOPHiA GENETICS projects revenue between $72M-$76M (10-17% growth) and adjusted EBITDA loss between $35M-$39M. The company expects to approach adjusted EBITDA breakeven by end of 2026 and achieve positive adjusted EBITDA in H2 2027.

SOPHiA GENETICS (Nasdaq: SOPH) has announced significant adoption of its MSK-ACCESS® and MSK-IMPACT® cancer testing applications powered by SOPHiA DDM™. Thirty-seven prominent institutions globally have adopted these recently launched Liquid Biopsy and Solid Tumor applications, with thirty-four specifically choosing MSK-ACCESS® within ten months of its launch.

Notable adopters include Heidelberg University Hospital, Hospital del Mar, Jewish General Hospital, and the Jiménez Díaz Foundation. The decentralized deployment enables institutions to conduct world-renowned testing in-house, offering less-invasive options for patients with potentially lower costs and faster turnaround times.

This milestone follows SOPHiA GENETICS' 2023 partnership with Memorial Sloan Kettering Cancer Center and their October 2024 agreement with AstraZeneca to accelerate MSK-ACCESS® deployment globally. The company launched MSK-IMPACT® for Solid Tumor testing in November 2024.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, before U.S. markets open. The company will host a conference call at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the financial results and business outlook. The call will be available via webcast on the SOPHiA GENETICS Investor Relations Website, with a replay option provided after the event.

SOPHiA GENETICS (SOPH) has launched the OncoPortal™ Mutation Tracker, a new longitudinal MRD tracking tool for oncology disease monitoring. This add-on module for the SOPHiA DDM™ Platform enables tracking of genomic variants across multiple time points in cancer patients.

The tool combines longitudinal tracking capabilities with next-generation sequencing (NGS) to detect cancer-specific genetic mutations at very low frequencies. Key features include flexible low frequency variant selection, customizable threshold settings, and reporting features that generate longitudinal graphical representations.

According to Dr. Philippe Menu, Chief Medical Officer, the ability to track low frequency variants longitudinally is revolutionary as it enables detection of minimal cancer traces that might escape traditional testing methods. Dr. Christophe Marzac from Gustave Roussy Institute praised the interface as a important solution for broader NGS adoption among oncologists.

SOPHiA GENETICS (SOPH) has globally launched MSK-IMPACT® powered with SOPHiA DDM™, a comprehensive genomic profiling application developed in collaboration with Memorial Sloan Kettering Cancer Center. The solution enables organizations worldwide to access advanced tumor profiling technologies with high accuracy and efficiency. The platform demonstrates exceptional performance with 99.3% positive agreement for SNV/Indel detection and 94.6% for CNV detection. SOFIVA GENOMICS in Taiwan is among the first adopters, expanding their tumor profiling capabilities. The workflow takes approximately five days from DNA extraction to final report, integrating OncoKB™ for enhanced analytical insights.